title: Hepatitis B core IgM antibody (anti-HBcIgM) among hepatitis B surface antigen (HBsAg) negative blood donors in Nigeria.
abstract: BACKGROUND
  Transfusion associated Hepatitis B virus (TAHBV) continues to be a major problem despite mandatory screening for Hepatitis B surface Antigen (HBsAg). Presence of HBsAg is the common method for detecting hepatitis B infection. Unfortunately, this marker is not detected during the window period of the infection. Nigeria being a developing country cannot afford DNA testing of all collected units of blood which serve as the only possibility of achieving zero risk of transfusion associated HBV. Five different serological makers of hepatitis B virus (HBV) infection were therefore assessed to evaluate the reliability of using HBsAg marker alone in diagnosis of HBV infection among blood donors and to detect the serological evidence of the infection at the window period. This will preclude the possibility of transmitting hepatitis B through transfusion of Hepatitis B surface antigen (HBsAg) negative blood in Nigeria.
  
  
  METHODS
  Between July and August 2009, 92 blood donors were enrolled for the study. The prevalence of 5 different markers of Hepatitis B virus infection was detected using Enzyme Linked Immunosorbent Assay (ELISA). Demographic factors were assessed during the study.
  
  
  RESULTS
  HBsAg and its antibody (anti-HBs) was detected in 18 (19.6%) and 14(15.2%) of the 92 blood donors respectively. Anti-HBc IgM was found in 12(13.0%) of the 92 blood donors while Hepatitis B envelope antigen (HBeAg) and its antibody (anti-HBe) were detected in 4(8.9%) and 12(26.7%) respectively from 45 donors sampled. HBeAg is a marker of high infectivity and appears after HBsAg. At least one serological marker was detected in 30(32.6%) of the blood donors. Five (5.4%) of the 92 donors had anti-HBc IgM as the only serological evidence of hepatitis B virus infection.
  
  
  CONCLUSIONS
  The result of this study shows that five donors have anti-HBcIgM as the only serological evidence of HBV infection. Inclusion of anti-HBcIgM in routine screening of blood donors in Nigeria should be encouraged. This is the first study to assess anti-HBcIgM in the country.
authors.affiliation: Department of Microbiology, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. megdeoti@yahoo.com
authors.forename: Margaret Oluwatoyin
authors.initials: MO
authors.lastname: Japhet
authors.forename: Olufisayo Adeyemi
authors.initials: OA
authors.lastname: Adesina
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Donbraye
authors.forename: Moses Olubusuyi
authors.initials: MO
authors.lastname: Adewumi
mesh_terms: D000293:Adolescent; D000328:Adult; D001782:Blood Donors; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009549:Nigeria; D055815:Young Adult
chemical_list: D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D007075:Immunoglobulin M
references.citation: J Med Virol. 1985 Jan;15(1):49-56
references.pmid: 3968544
references.citation: Vox Sang. 2001;81(2):139
references.pmid: 11555477
references.citation: Gut. 1999 Aug;45(2):284-8
references.pmid: 10403743
references.citation: Blood. 2002 Oct 1;100(7):2637-41
references.pmid: 12239179
references.citation: J Infect. 2005 Oct;51(3):263
references.pmid: 16125778
references.citation: N Engl J Med. 2002 May 30;346(22):1682-3
references.pmid: 12037146
references.citation: Med Princ Pract. 2006;15(5):368-72
references.pmid: 16888395
references.citation: J Med Virol. 2000 Dec;62(4):450-5
references.pmid: 11074473
references.citation: Ann Intern Med. 1984 Dec;101(6):733-8
references.pmid: 6437308
references.citation: N Engl J Med. 1978 Oct 26;299(17):958
references.pmid: 692609
references.citation: J Glob Infect Dis. 2010 Sep;2(3):246-7
references.pmid: 20927286
references.citation: Transfusion. 2003 Oct;43(10):1442-8
references.pmid: 14507277
references.citation: Vox Sang. 2006 Oct;91(3):237-43
references.pmid: 16958836
references.citation: East Afr Med J. 1995 Nov;72(11):719-21
references.pmid: 8904063
references.citation: Vox Sang. 2004 Feb;86(2):83-91
references.pmid: 15023176
references.citation: Transfusion. 1993 Mar;33(3):212-6
references.pmid: 8438221
references.citation: J Viral Hepat. 2004 Mar;11(2):97-107
references.pmid: 14996343
references.citation: Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68
references.pmid: 10704474
references.citation: Med J Armed Forces India. 2007 Oct;63(4):350-2
references.pmid: 27408047
references.citation: Clin Chem. 1997 Aug;43(8 Pt 2):1500-6
references.pmid: 9265901
references.citation: Transfusion. 1995 Jan;35(1):5-12
references.pmid: 7998069
references.citation: N Engl J Med. 1978 Jun 22;298(25):1379-83
references.pmid: 652005